Allergic Bronchopulmonary Aspergillosis clinical trials at University of California Health
1 research study open to eligible people
Open-Label Study to Evaluate Efficacy and Safety of Ibrexafungerp in Patients With Refractory or Intolerant Fungal Diseases
open to eligible people ages 18 years and up
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
at UC Davis UCSF
Our lead scientists for Allergic Bronchopulmonary Aspergillosis research studies include Peter Chin-Hong, MD.